ArticleFrontiers in nutrition2026
Excessive weight loss during alternate day modified fasting increases the risk of hyperuricemia and muscle loss.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Obesity has become a significant contributor to non-communicable diseases worldwide, making it imperative to explore effective weight-loss methods. Alternate day modified fasting (ADMF) has emerged as a popular approach, but its effects on uric acid (UA) dynamics and body composition in Chinese populations remain unclear. This study aimed to investigate whether ADMF could change body composition and cardiometabolic parameters in individuals with obesity, and to analyze the correlation between changes in body composition indices and UA levels. Methods: A total of 35 adults were recruited and completed a 62-day trial, which consisted of a 32-day high-controlled fasting phase (HCFP) and a 30-day low-controlled fasting phase (LCFP). Body composition was measured by bioelectrical impedance analysis, and blood pressure (BP) and metabolic parameters were assessed at baseline, day 16, day 32, and day 62. Results: Of the 35 participants (20 males, 15 females; mean age 36.23 ± 8.98 years; baseline body weight 100.02 ± 16.89 kg; baseline BMI 35.47 ± 4.15 kg/m Conclusion: A phased ADMF intervention was associated with effective reduction in adiposity and improvement in cardiometabolic risk factors. However, the transient hyperuricemia and lean muscle loss during the intensive phase suggest that UA monitoring and muscle-preserving strategies may be considered to optimize the safety and efficacy of ADMF protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.